Literature DB >> 12375304

Parametric models for accelerated and long-term survival: a comment on proportional hazards.

Paul Frankel1, Jeffrey Longmate.   

Abstract

The Cox proportional hazards model (CPH) is routinely used in clinical trials, but it may encounter serious difficulties with departures from the proportional hazards assumption, even when the departures are not readily detected by commonly used diagnostics. We consider the Gamel-Boag (GB) model, a log-normal model for accelerated failure in which a proportion of subjects are long-term survivors. When the CPH model is fit to simulated data generated from this model, the results can range from gross overstatement of the effect size, to a situation where increasing follow-up may cause a decline in power. We implement a fitting algorithm for the GB model that permits separate covariate effects on the rapidity of early failure and the fraction of long-term survivors. When effects are detected by both the CPH and GB methods, the attribution of the effect to long-term or short-term survival may change the interpretation of the data. We believe these examples motivate more frequent use of parametric survival models in conjunction with the semi-parametric Cox proportional hazards model. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12375304     DOI: 10.1002/sim.1273

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Breast Cancer Survival Analysis: Applying the Generalized Gamma Distribution under Different Conditions of the Proportional Hazards and Accelerated Failure Time Assumptions.

Authors:  Alireza Abadi; Farzaneh Amanpour; Chris Bajdik; Parvin Yavari
Journal:  Int J Prev Med       Date:  2012-09

2.  Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment.

Authors:  Patricia Tai; Judith-Anne W Chapman; Edward Yu; Dennie Jones; Changhong Yu; Fei Yuan; Lee Sang-Joon
Journal:  BMC Cancer       Date:  2007-02-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.